Dendritic cells stimulated with cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-α-expressing tumor cells effectively reduce outgrowth of established tumors in vivo

Cancer Science

Volumn 99, Issue 8, 2008, Pages 1663-1669

  Hiraide, Ayako ^a   Hiroishi, Kazumasa ^a   Eguchi, Junichi ^a   Ishii, Shigeaki ^a   Doi, Hiroyoshi ^a   Imawari, Michio ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; GANGLIOTETRAOSYLCERAMIDE; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELL STIMULATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOLYSIS; DENDRITIC CELL; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INOCULATION; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOSINE NUCLEOTIDES; DENDRITIC CELLS; FLOW CYTOMETRY; GENE EXPRESSION; GUANOSINE; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; INTERLEUKIN-12; KILLER CELLS, NATURAL; MICE; OLIGONUCLEOTIDES; UP-REGULATION;

EID: 49749142638     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00858.x     Document Type: Article

References (37)

1. Becker Y. Dendritic cell activity against primary tumors: An overview. In Vivo 1993; 7: 187-91.
2. Zeid N, Muller H. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993; 25: 338-43.
3. Furihata M, Ohtsuki Y, Ido E et al. HLA-DR antigen- and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma: their distribution in relation to prognosis. Virchows Arch B 1992; 61: 409-14.
4. Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi K. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 1990; 66: 2012-16.
5. Giannini A, Bianchi S, Messerini L et al. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma. Pathol Res Pract 1991; 187: 496-502.
6. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-80.
7. Krieg AM, Wagner H. Causing a commotion in the blood: Immunotherapy progresses from bacteria to bacterial DNA. Immunol Today 2000; 21: 521-6.
8. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
9. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997; 94: 10833-7.
10. Brunner C, Seiderer J, Schlamp A et al. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in.vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 2000; 165: 6278-86.
11. Heckelsmiller K, Beck S, Rall K et al. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 2002; 32: 3235-45.
12. Hiraoka K, Yamamoto S, Otsuru S et al. Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J Immunol 2004; 173: 4297-307.
13. Pashenkov M, Goess G, Wagner C et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006; 24: 5716-24.
14. Juang Y, Lowther W, Kellum M et al. Primary activation of interferon A and interferon B gene transcription by interferon regulatory factor 3. Proc Natl Acad Sci USA 1998; 95: 9837-42.
15. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-α genes by positive feedback through interferon regulatory factor-7. EMBO J 1998; 17: 6660-9.
16. Okada H, Villa L, Attanucci J et al. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther 2001; 8: 1157-66.
17. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995; 103: 161-79.
18. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001; 166: 2961-9.
19. von Hoegen P, Zawatzky R, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-α/β. Cellular Immunol 1990; 126: 80-90.
20. Hiroishi K, Tuting T, Lotze MT. IFN-α-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 2000; 164: 567-72.
21. Santini SM, Lapenta C, Logozzi M et al. Type 1 interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000; 191: 1777-88.
22. Ishii S, Hiroishi K, Eguchi J, Hiraide A, Imawari M. Dendritic cell therapy with interferon-α synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model. Gene Ther 2006; 13: 78-87.
23. Hiraide A, Hiroishi K, Ishii S, Eguchi J, Imawari M. Cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-α-expressing tumor cells effectively induce dendritic cell maturation in vitro. Anticancer Res 2006; 26: 211-18.
24. Hiroishi K, Tüting T, Tahara H, Lotze MT. Interferon-α gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models. Gene Ther 1999; 6: 1988-94.
25. Yi AK, Krieg AM. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of IκBα and IκBβ and sustained activation of nuclear factor-κB/ c-Rel. J Immunol 1998; 160: 1240-5.
26. Eguchi J, Hiroishi K, Ishii S, Mitamura K. Interferon-α and interleukin-12 gene therapy of cancer: Interferon-α induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing. Cancer Immunol Immunother 2003; 52: 378-86.
27. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-90.
28. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99: 351-8.
29. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 2005; 11: 748-56.
30. Wolf SF, Temple PA, Kobayashi M et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074-81.
31. Chan SH, Perussia B, Gupta JW et al. Induction of interferon γ production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-79.
32. Kodama T, Takeda K, Shimozato O et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999; 29: 1390-6.
33. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999; 73: 329-68.
34. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
35. + DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 2003; 33: 827-33.
36. Hemmi H, Kaisho T, Takeda K, Akira S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 2003; 170: 3059-64.
37. 2. Cancer Sci 2003; 94: 1091-8.